297 related articles for article (PubMed ID: 32674116)
1. Reproductive Endocrinology Reference Intervals for Transgender Women on Stable Hormone Therapy.
Greene DN; Schmidt RL; Winston McPherson G; Rongitsch J; Imborek KL; Dickerson JA; Drees JC; Humble RM; Nisly N; Dole NJ; Dane SK; Frerichs J; Krasowski MD
J Appl Lab Med; 2021 Jan; 6(1):15-26. PubMed ID: 32674116
[TBL] [Abstract][Full Text] [Related]
2. Reproductive Endocrinology Reference Intervals for Transgender Men on Stable Hormone Therapy.
Greene DN; Schmidt RL; Winston-McPherson G; Rongitsch J; Imborek KL; Dickerson JA; Drees JC; Humble RM; Nisly N; Dole NJ; Dane SK; Frerichs J; Krasowski MD
J Appl Lab Med; 2021 Jan; 6(1):41-50. PubMed ID: 33241847
[TBL] [Abstract][Full Text] [Related]
3. Reference Intervals for Clinical Chemistry Analytes for Transgender Men and Women on Stable Hormone Therapy.
Humble RM; Greene DN; Schmidt RL; Winston McPherson G; Rongitsch J; Imborek KL; Nisly N; Dole NJ; Dane SK; Frerichs J; Krasowski MD
J Appl Lab Med; 2022 Sep; 7(5):1131-1144. PubMed ID: 35584132
[TBL] [Abstract][Full Text] [Related]
4. Hematology reference intervals for transgender adults on stable hormone therapy.
Greene DN; McPherson GW; Rongitsch J; Imborek KL; Schmidt RL; Humble RM; Nisly N; Dole NJ; Dane SK; Frerichs J; Krasowski MD
Clin Chim Acta; 2019 May; 492():84-90. PubMed ID: 30771301
[TBL] [Abstract][Full Text] [Related]
5. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial.
Burinkul S; Panyakhamlerd K; Suwan A; Tuntiviriyapun P; Wainipitapong S
J Sex Med; 2021 Jul; 18(7):1299-1307. PubMed ID: 34274044
[TBL] [Abstract][Full Text] [Related]
6. Changes in Serum Testosterone and Adrenal Androgen Levels in Transgender Women With and Without Gonadectomy.
Collet S; Gieles NC; Wiepjes CM; Heijboer AC; Reyns T; Fiers T; Lapauw B; den Heijer M; T'Sjoen G
J Clin Endocrinol Metab; 2023 Jan; 108(2):331-338. PubMed ID: 36201493
[TBL] [Abstract][Full Text] [Related]
7. SERUM HORMONE CONCENTRATIONS IN TRANSGENDER INDIVIDUALS RECEIVING GENDER-AFFIRMING HORMONE THERAPY: A LONGITUDINAL RETROSPECTIVE COHORT STUDY.
Chantrapanichkul P; Stevenson MO; Suppakitjanusant P; Goodman M; Tangpricha V
Endocr Pract; 2021 Jan; 27(1):27-33. PubMed ID: 33471729
[TBL] [Abstract][Full Text] [Related]
8. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial.
Moutos D; Smith S; Zacur H
Contraception; 1995 Aug; 52(2):105-9. PubMed ID: 8536446
[TBL] [Abstract][Full Text] [Related]
9. TESTOSTERONE LEVELS ACHIEVED BY MEDICALLY TREATED TRANSGENDER WOMEN IN A UNITED STATES ENDOCRINOLOGY CLINIC COHORT.
Liang JJ; Jolly D; Chan KJ; Safer JD
Endocr Pract; 2018 Feb; 24(2):135-142. PubMed ID: 29144822
[TBL] [Abstract][Full Text] [Related]
10. Sublingual Estradiol Is Associated with Higher Estrone Concentrations than Transdermal or Injectable Preparations in Transgender Women and Gender Nonbinary Adults.
Cirrincione LR; Winston McPherson G; Rongitsch J; Sadilkova K; Drees JC; Krasowski MD; Dickerson JA; Greene DN
LGBT Health; 2021; 8(2):125-132. PubMed ID: 33439749
[No Abstract] [Full Text] [Related]
11. Uncertainty of measurement for 14 immunoassay analytes: application to laboratory result interpretation.
Çubukçu HC; Yavuz Ö; Devrim E
Scand J Clin Lab Invest; 2019; 79(1-2):117-122. PubMed ID: 30626224
[TBL] [Abstract][Full Text] [Related]
12. Reference intervals for biochemical analytes in transgender individuals on hormone therapy.
Bezuidenhout MC; Conradie-Smit M; Dave JA; de Vries E; Ross IL; Zemlin AE
Ann Clin Biochem; 2022 May; 59(3):183-192. PubMed ID: 35044249
[TBL] [Abstract][Full Text] [Related]
13. A mouse model to investigate the impact of testosterone therapy on reproduction in transgender men.
Kinnear HM; Constance ES; David A; Marsh EE; Padmanabhan V; Shikanov A; Moravek MB
Hum Reprod; 2019 Oct; 34(10):2009-2017. PubMed ID: 31585007
[TBL] [Abstract][Full Text] [Related]
14. Addition of progesterone to feminizing gender-affirming hormone therapy in transgender individuals for breast development: a randomized controlled trial.
Dijkman BAM; Helder D; Boogers LS; Gieles NC; van Heesewijk JO; Slaa ST; Liberton NPTJ; Wiepjes CM; de Blok CJM; den Heijer M; Dreijerink KMA
BMC Pharmacol Toxicol; 2023 Dec; 24(1):80. PubMed ID: 38124194
[TBL] [Abstract][Full Text] [Related]
15. MANAGEMENT OF ENDOCRINE DISEASE: Optimal feminizing hormone treatment in transgender people.
Glintborg D; T'Sjoen G; Ravn P; Andersen MS
Eur J Endocrinol; 2021 Jun; 185(2):R49-R63. PubMed ID: 34081614
[TBL] [Abstract][Full Text] [Related]
16. Endocrinological and ovarian histological investigations in assigned female at birth transgender people undergoing testosterone therapy.
Borrás A; Manau MD; Fabregues F; Casals G; Saco A; Halperin I; Mora M; Goday A; Barral Y; Carmona F
Reprod Biomed Online; 2021 Aug; 43(2):289-297. PubMed ID: 34244072
[TBL] [Abstract][Full Text] [Related]
17. Age-specific reference values improve the diagnostic performance of AMH in polycystic ovary syndrome.
Evliyaoglu O; Imöhl M; Weiskirchen R; van Helden J
Clin Chem Lab Med; 2020 Jul; 58(8):1291-1301. PubMed ID: 32069226
[TBL] [Abstract][Full Text] [Related]
18. Risk assessment of transgender people: implementation of a demasculinizing-feminizing rodent model including the evaluation of thyroid homeostasis.
Tammaro A; Lori G; Martinelli A; Cancemi L; Tassinari R; Maranghi F
Biol Direct; 2024 Jan; 19(1):5. PubMed ID: 38166984
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
